AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00242736
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00242762
- Locations
- 🇪🇸
Research Facility, Murcia, Spain
🇪🇸Research Site, Sevilla, Spain
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00242775
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 370
- Registration Number
- NCT00242372
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 270
- Registration Number
- NCT00242346
- Locations
- 🇨🇦
Research Site, Saskatoon, Saskatchewan, Canada
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00242307
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1900
- Registration Number
- NCT00242411
- Locations
- 🇳🇴
Research Site, Årnes, Norway
Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 551
- Registration Number
- NCT00242320
- Locations
- 🇨🇳
Altana Pharma/Nycomed, Tau-Yuan, Taiwan
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 570
- Registration Number
- NCT00242294
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Oharma Corporation, Osaka, Japan
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT00241449
- Locations
- 🇬🇧
Research Site, York, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath